Nemaura Medical, Inc. · OTC:NMRD
Nemaura Medical — Investor Presentation (May 2016)
23 slides from Nemaura Medical's investor presentation, May 13, 2016
Slide 1: Nemaura Medical Corporate Presentation May 2016
ee WN) NEMAURA MEDICAL (OTCBB: NMRD) Better Diagnostics for Life Corporate Presentation May 2016
Slide 2: Forward-looking statements
This presentation includes forward-looking statements that are subject to many risks and uncertainties. These forward-looking statements, such as statements about Nemaura’s short-term and long-term growth strategies, can sometimes be identified by use of terms such as “intend,” “expect,” “plan,” “es
Slide 3: Nemaura Medical overview
vNemaura Medical is a UK-based innovator of unique wearable-tech health tracking and diagnostics products that have evolved out of our core area of expertise in transdermal drug delivery. vWe believe our proprietary technology offers material advantages over the competition that will dramatically im
Slide 4: Market Dynamics
Market Dynamics A large and growing opportunity $13.8 B (2015) $31.27 B (2020) Global Wearable Technology market, $19.1 B (2015) $24.6 B (2020) Global Care Device Market Adults with Diabetics Worldwide Europe Glucose Monitoring Market U.S. Glucose Monitoring Market $4.8 B+ © Self-monitoring: $4.1B b
Slide 5: One platform technology, multiple product applications
One platform technology, multiple product applications Our proprietary technology platform, known as BEAT™, consists of a daily adhesive disposable skin-patch integrated with a reusable Bluetooth-enabled sensor that collects and quantifies a wide range of analytes present within interstitial fluid.
Slide 6: BEAT Platform Summary
BEAT” Platform Summary Ability to address a wide variety of patient needs Wireless Wired/Integrated Daily-disposable adhesive skin-patch integrated with Bluetooth-enabled sensor Daily-disposable adhesive skin-patch - ‘Watch device Optional Wireless Smartwatch Handheld Reader ) NEMAURA
Slide 7: sugarBEAT commercial launch expected by end of Q4 2016
vsugarBEAT® commercial launch expected by end of Q4 2016 (CE Mark issued during Q1 2016) vInterim clinical data on increased measurement frequency for sugarBEAT® CGM released in April 2016 vsugarBEAT® U.S. clinical trials pending regulatory approval through the PMA route vAdditional products using B
Slide 8: sugarBEAT usage steps
vCleanse and prep skin vApply patch to arm, leg or abdomen vApproximate 30 minutes warm-up period vSensor measures glucose within extracted interstitial fluid vSensor records a reading every 5 minutes and transmits via Bluetooth to pre-downloaded App on user’s smart device vUser’s smart device can b
Slide 9: sugarBEAT Competitive Landscape
sugarBEAT° Competitive Landscape Integrity Company Senseorics Utrasound Glucose Ghucose-—«=«Ghcase «cose ise : Technology es ie | € zg seroma Reliability 2 2 7 “ 2s _ 114% 168% 108% 9.0% 114% Heh Reliability 99% 919% 99.6% bie 96% 95.3% arke EGA) (overt) (veld) (ovenit) —pepvennia (Overt) (vat) Pati
Slide 10: sugarBEAT Development Milestones
sugarBEAT° Development Milestones bj lopment Reched CE Mik ng SEAT? natn PC “ Release wireless prototype “ Meet with FDA for PMA roadmap i NEMAURA 10
Slide 11: Targeted Market Size
Targeted Market Size By diabetic population USA 25.8 39 219 Saudi Arabia 33 0.5 28 Note: 1. Using the UK figures asa proxy, the total numberof Type 1 and Insulin dependent Type 2 disbetis has been estimated at 15% ofthe total global diabticpopulaton 2. The other countias in Europe have nctbeen inclu
Slide 12: DB Pharma joint venture and $10 million investment
In exchange for purchasing $10 million of Nemaura Medical stock (5 million shares), DB Pharma and Nemaura entered into an equal joint venture granting DB an exclusive license to market the sugarBEAT® system across Europe, to commence upon final regulatory approval: vDB Pharma is a UK-based specialty
Slide 13: Clinical Data
Clinical Data Evaluation of Clinical Data for Continuous Glucose Monitoring Study Criteria and Performance Metrics The following criteria have been employed to measure the performance of the sugarBEAT® device. Parameter Study 1 Study 2 Reference Device HemoCue Laboratory finger prick ghicose meter H
Slide 14: Clinical Trials for sugarBEAT
Clinical Trials for sugarBEAT° A © Clinical Data in Type Land II Diabetics 100 patient day: 30 patients, 3 or 4 visits, 12 — 14 hr wear/day — ZERO skin ittitation recorded Recent data indicates MARD of <15% achievable InvasiveCGM ——-Dexcom G4* 4634 10.8% 84.50% 15.10% 0.94 Invasive CGM Medtronic Enl
Slide 15: Clinical Dataset Example
A, 6) Clinical Dataset Example Stage 2 Study: Example of CGM sensitivity of non-diabetic within euglycemic range Blood Glucose Concentration (mmol/L) vs. Time (mins) Glucose Drink aa 1 taken at 80 Glucose Drink 2 taken at 160 Dinner taken ‘minutes at 440 tes i 8.50 _ Fruit taken ES No further food i
Slide 16: Clinical Dataset Example - Study
Clinical Dataset Example - Study 2 Stage 2 Study: Example 1 of CGM sensitivity in insulin dependent Type 2 A, Blood Glucose Concentration (mmol/L) vs. Time (mins) Dinner taken at 360 minutes Snack at 600 minutes 20 units Equilibrated Insulin at within 1 hour A. 240 minutes Calibrated Blood Glucose C
Slide 17: Clinical Dataset Example - Study
Clinical Dataset Example - Study 2 Stage 2 Study: Example 2 of CGM sensitivity in insulin dependent Type 2 A, Blood Glucose Concentration (mmol/L) vs. Time (mins) Insulin 20 ae: 4 units at 420 minutes Boas § 3 2 = 2 i ay zou ’ I Dinner at 5 Equilbrated 480 minutes FAM within 1 hour 120 150 180 210 2
Slide 18: Pipeline Opportunities
Pipeline Opportunities Reverse iontophoresis technology can be expanded to extract and measure other substances present in the interstitial fluid Potential Substance in Interstitial Fluids Uses Desert Phenylalanine monitoring to ensure that the level is sufficiently suppressed Phenylalanine Phenylke
Slide 19: Current Financials & Capital Markets
Current Financials & Capital Markets Overview Cash $9.8 mm Market Cap $307.5 mm Related Party Debt $0.5 mm Shares Outstanding 205.6 mith, REE
Slide 20: Management team
Dr. Dewan FazlulHoque Chowdhury CEO and President §Over 18 years’ experience in the pharmaceutical and medical device industry and holder of over 50 patents across more than 15 patent families §2009-Present: President, Chief Executive Officer and Board Director at Nemaura in charge of research and d
Slide 21: Advisors
Madhavi Saharawi Medical Device Advisor §Over 16 years of experience in Quality Assurance and Assurance and Regulatory Affairs (QA & RA) including 14 years plus in Class I to Class III Medical devices, and a former Notified Body Technical File Reviewer §2015-2016: UK &US Director of Regulatory Affai
Slide 22: Intellectual Property
Intellectual Property EU, USA, JP, CA+ others Patch Construction Granted in EU, 2028 Pending elsewhere EU, USA, JP, CA Algorithm —1 + others Pending 2032 2 EU, USA, JP, CA Algorithm —2 + others Pending 2035 Intemal Calibration Gee 2021
Slide 23: Corporate Structure
I Corporate Structure e Nemaura Medical Inc. Region Green Ltd. evp Dermal Diagnostics Ltd. Trial Clinic Ltd. (England & Wales) England & Wales)